Findings

What do systematic reviews say?

6 questions · 6 findings · 4 reviews

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 2 · 33.3%High 0 · 0%

Serious adverse events · people with chronic gout

Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
RR 1.93 [0.48, 7.8]
2 studies · 453 participants
Moderate

Adverse events · Patients with ileal pouch‐anal anastomosis

The review found no eligible studies for this question.

1 finding from 1 review

Adverse events · participants with chronic prostatitis/chronic pelvic pain syndrome

1 finding from 1 review

Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 110 participants
Low

Withdrawals due to adverse events · people with chronic gout

Allopurinol showed no clear difference in withdrawal due to adverse events compared with benzbromarone (low certainty).

1 finding from 1 review

Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
RR 0.8 [0.18, 3.58]
2 studies · 91 participants
Low

Withdrawals due to adverse events · people with chronic gout

Allopurinol showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Allopurinol for chronic gout 2014 · Cochrane Headline outcomes only
RR 1.36 [0.61, 3.08]
2 studies · 453 participants
Moderate

Other adverse events and complications · people with liver metastases

The review found no eligible studies for this question.

1 finding from 1 review

Electrocoagulation for liver metastases 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found